<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03044379</url>
  </required_header>
  <id_info>
    <org_study_id>MTN-026/ IPM 038</org_study_id>
    <nct_id>NCT03044379</nct_id>
  </id_info>
  <brief_title>Dapivirine Gel Rectal Safety and PK Study</brief_title>
  <official_title>A Randomized, Double Blind, Placebo-Controlled, Phase 1 Safety and Pharmacokinetic Study of Dapivirine Gel (0.05%) Administered Rectally to HIV-1 Seronegative Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>International Partnership for Microbicides, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>International Partnership for Microbicides, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dapivirine Gel Rectal Safety and PK Study&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Randomized, Double Blind, Placebo-Controlled Phase 1 Safety and Pharmacokinetic Study of&#xD;
      Dapivirine Gel (0.05%) Administered Rectally to HIV-1 Seronegative Adults&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Current program is on hold, not for safety reason&#xD;
  </why_stopped>
  <start_date type="Actual">September 29, 2015</start_date>
  <completion_date type="Anticipated">November 2017</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety To characterize the systemic and compartmental pharmacokinetics of dapivirine gel following rectal application.</measure>
    <time_frame>9-12 months</time_frame>
    <description>To evaluate the safety of dapivirine gel formulation when applied rectally.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acceptability</measure>
    <time_frame>9-12 months</time_frame>
    <description>To identify product attributes considered likely to challenge and facilitate future sustained use of rectally applied dapivirine gel.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>HIV 1 Infection</condition>
  <arm_group>
    <arm_group_label>Dapivirine Gel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will be randomized to receive a single dose of dapivirine gel rectally, followed by 7 daily doses of the same product to be administered under direct observation in the clinic.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Gel HEC</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will be randomized to receive the universal HEC placebo gel rectally, followed by 7 daily doses of the same product to be administered under direct observation in the clinic.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapivirine gel (0.05%)</intervention_name>
    <description>MTN-026/IPM 038 will use the HTI pre-filled applicator, the same applicator that has been utilized in other rectal studies.</description>
    <arm_group_label>Dapivirine Gel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Universal HEC placebo gel</intervention_name>
    <arm_group_label>Placebo Gel HEC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age of 18 - 45 years (inclusive), verified per site SOP&#xD;
&#xD;
          -  Able and willing to provide written informed consent&#xD;
&#xD;
          -  HIV-1/2 uninfected at Screening and Enrollment, per applicable algorithm in Appendix&#xD;
             II and willing to receive HIV test results&#xD;
&#xD;
          -  Able and willing to provide adequate locator information, as defined in site SOP&#xD;
&#xD;
          -  Available to return for all study visits and willing to comply with study&#xD;
             participation requirements&#xD;
&#xD;
          -  In general good health at Screening and Enrollment, as determined by the site IoR or&#xD;
             designee&#xD;
&#xD;
          -  Per participant report, a history of consensual RAI at least once in the past calendar&#xD;
             year&#xD;
&#xD;
          -  Willing to not take part in other research studies involving drugs, medical devices,&#xD;
             genital products, or vaccines for the duration of study participation, including the&#xD;
             time between Screening and Enrollment&#xD;
&#xD;
        Exclusion Criteria: At Screening:&#xD;
&#xD;
          -  Hemoglobin Grade 1 or higher*&#xD;
&#xD;
          -  Platelet count Grade 1 or higher*&#xD;
&#xD;
          -  White blood count Grade 2 or higher*&#xD;
&#xD;
          -  Serum creatinine 1.3 the site laboratory upper limit of normal (ULN)&#xD;
&#xD;
          -  International normalized ratio (INR) 1.5 the site laboratory ULN&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) or alanine transaminase (ALT) Grade 1 or higher*&#xD;
&#xD;
          -  Positive for hepatitis C antibody&#xD;
&#xD;
          -  Positive for hepatitis B surface antigen&#xD;
&#xD;
          -  History of inflammatory bowel disease by participant report&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <study_first_submitted>September 6, 2016</study_first_submitted>
  <study_first_submitted_qc>February 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 7, 2017</study_first_posted>
  <last_update_submitted>February 6, 2017</last_update_submitted>
  <last_update_submitted_qc>February 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dapivirine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

